News

VIDEO: Exploring SYMPLICITY’s failure, Part 2


 

AT ACC 14

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to measure its effectiveness.

In Part 2 of our interview, Dr. Prakash Deedwania and Dr. George Bakris explore the options, and don’t miss the chance to talk about the controversial new hypertension guidelines.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

CARDIA: Trajectory of blood pressure in young adults predicts later CAC
MDedge Internal Medicine
New stroke guidelines focus on women’s risks
MDedge Internal Medicine
Beta-blockers lose luster for hypertension therapy
MDedge Internal Medicine
The demise of renal artery stenting
MDedge Internal Medicine
Childhood glomerular disease associated with adult hypertension
MDedge Internal Medicine
Systolic variability after intracerebral hemorrhage raises odds of death, disability
MDedge Internal Medicine
VIDEO: What explains SYMPLICITY HTN-3’s failure?
MDedge Internal Medicine
Ineffective renal denervation blamed for trial’s failure
MDedge Internal Medicine
Too much or too little sodium may boost cardiovascular risk
MDedge Internal Medicine
One in four patients with hypertension nonadherent to therapy
MDedge Internal Medicine

Related Articles